Stay updated on Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial page.

Latest updates to the Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page has updated the reference for the study on crizotinib versus chemotherapy in advanced ALK-positive lung cancer, removing an erratum note and updating the version number from v2.15.0 to v2.15.2.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed trial descriptions and inclusion criteria for a clinical trial on Non-Small Cell Lung Cancer, while adding new collaborators and a revision number.SummaryDifference14%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check66 days agoChange DetectedThe page has added the name 'Endeavor Health' while removing references to 'NorthShore University HealthSystem' and a notice about NLM-NCBI services experiencing heavy traffic.SummaryDifference0.8%
- Check87 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.7%
Stay in the know with updates to Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial page.